Roderick Dashwood

Roderick Dashwood is the Director of the Center for Epigenetics & Disease Prevention and a Professor in the Department of Translational Medical Sciences at Texas A&M University School of Medicine. His research focuses on epigenetic mechanisms in cancer prevention, particularly colorectal cancer, leveraging dietary agents and immunomodulatory therapies. He leads translational studies integrating epigenetic regulation, drug combinations (e.g., erlotinib/sulindac), and biomarker discovery.

Key research areas include:

• Epigenetic targeting of histone modifiers (e.g., PRC2 complexes, bromodomain proteins)
• Immunogenicity modulation in gastrointestinal malignancies
• Role of dietary polyphenols (e.g., sulforaphane, mango polyphenols) in inflammation and cancer
• Mechanisms of chemosensitization and drug synergy

Recent work highlights the antitumor efficacy of low-dose erlotinib/sulindac combinations and the impact of neonatal inflammation on adult colitis. His publications emphasize translational advances, including metabolomic profiling and microbiome interactions in cancer models.

Labs/Teams: Directs the Center for Epigenetics & Disease Prevention, collaborating with Texas A&M AgriLife Research and the Texas A&M Health Science Center.